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Herein, we review the association between vitreomacular adhesion (VMA) and neovascular age-related macular degeneration
(AMD). Meta-analyses have shown that eyes with neovascular AMD are twice as likely to have VMA as normal eyes. VMA
in neovascular AMD may induce inflammation, macular traction, decrease in oxygenation, sequestering of vascular endothelial
growth factor (VEGF), and other cytokines ormay directly stimulate VEGF production. VMAmay also interfere with the treatment
effects of anti-VEGF therapy, which is the standard treatment for neovascular AMD, and releasing VMA can improve the treatment
response to anti-VEGF treatment in neovascular AMD. We also reviewed currently available methods of relieving VMA.
1. Introduction
Age-related macular degeneration (AMD) is one of the
leading causes of severe visual loss in developed countries and
affects approximately 8.7% of elderly people >55 years old [1,
2]. Visual loss from this disease is mainly due to neovascular
AMD or geographic atrophy (GA), and neovascular AMD
accounts for 10% to 15% of patients with AMD [3]. Neovas-
cular AMD is characterized by choroidal neovascularization
(CNV), which is promoted by vascular endothelial growth
factor (VEGF) and VEGF-A in particular [4]. A number of
studies have identified risk factors for progression to neovas-
cular AMD, including aging, cigarette smoking, and genetic
factors [5]. Several studies have also postulated that vitreo-
macular adhesion (VMA) is associated with AMD pathogen-
esis or progression, and herein we review effects of VMA on
neovascular AMD.
Krebs et al. first reported an increased incidence of VMA
in eyes with neovascular AMD (18/50 [36%]) compared with
dry AMD (4/57 [7%]) and controls (6/56 [11%]) [6]. Mojana
et al. demonstrated a higher incidence of VMA in eyes with
neovascular AMD compared with controls (27.8% versus
16%) [7]. In addition, a paired eye study revealed an increased
rate of VMA in eyes with neovascular AMD compared with
contralateral eyes which had dry AMD or no sign of AMD
[8]. Roller et al. showed that progression of AMD, including
geographic atrophy and CNV, was observed more frequently
in nonvitrectomized eyes compared with vitrectomized eyes
[9]. Together, these studies led us to speculate VMAmight be
a risk factor for the development of neovascular AMD and,
if so, VMA might be a modifiable risk factor for neovascular
AMD.
Currently, intravitreal anti-VEGF injections have been
established as the standard treatment for neovascular AMD
[10]. However, the study of ranibizumab in patients with sub-
foveal choroidal neovascularization secondary to age-related
macular degeneration (SUSTAIN) showed that 26% of AMD
patients were nonresponders to ranibizumab and showed no
initial gain of vision or gain of vision during the course of
treatment [11]. Another study reported that up to 45% of
patients with neovascular AMDwere nonresponders to beva-
cizumab [12]. Lee andKoh reported that VMAhas an adverse
effect on visual outcomes following anti-VEGF treatment,
and studies by U¨ney et al. and Nomura et al. also showed
the same results [13–15]. Thus, VMA might be a possible
characteristic of nonresponders, and releasingVMAmight be
a feasible method to improve responses to anti-VEGF treat-
ment in some eyes with VMA and neovascular AMD.
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The purpose of this review is to understand the asso-
ciations between VMA and neovascular AMD and suggest
possible treatment options for VMA with neovascular AMD.
2. Definitions
2.1. Posterior Vitreous Detachment. The vitreous consists of
water (98%) and structural macromolecules, including colla-
gen and hyaluronan [16, 17].The posterior vitreous is attached
to the internal limiting membrane (ILM) of the retina by the
macromolecular attachment complex including fibronectin
and laminin. Posterior vitreous detachment (PVD) is defined
as the dehiscence between the posterior vitreous and ILM.
The vitreous gradually liquefies with age so that more than
half of vitreous is liquid by the eighth decade [18]. PVD usu-
ally initiates as a focal detachment in the perifoveal macula,
with persistent attachment to the fovea and optic nerve head
[19]. Complete PVD describes the complete separation of the
vitreous from the macula and optic nerve head. Incomplete
or partial PVD naturally progresses to complete PVD.
Anomalous PVD may occur when vitreous liquefaction
outpaces vitreoretinal dehiscence or abnormal adhesion is
present between posterior vitreous and ILM. If anomalous
PVD occurs in the macular area, macular hole or macular
pucker may develop [16]. Retinal tears or retinal detachment
can also occur if the abnormal adhesion exists in the periph-
eral retina in anomalous PVD.
2.2. Vitreomacular Adhesion. With the development of opti-
cal coherence tomography (OCT), the vitreomacular inter-
face (VMI) can be conveniently assessed. The international
vitreomacular traction study (IVTS) group proposed the clas-
sification of vitreomacular adhesion, traction, and macular
hole according to anatomic features detected with OCT [20].
The vitreous and ILM are completely adherent at birth, so
the concept of vitreoretinal adhesion is a normal anatomic
state. However, the term VMA is clinically defined as the
vitreous being attached within a 3-mm radius of the fovea,
with surrounding separation of the cortical vitreous above the
neurosensory retina [20, 21]. In addition, the retina should
have no changes in surface contour or morphologic features
on OCT. VMA can be subclassified as focal (≤1500𝜇m) or
broad (>1500𝜇m) based on the size of the adhesion. More-
over, VMA should be referred to as concurrent when VMA is
associated with retinal diseases (such as AMD, diabetic mac-
ular edema, or retinal vein occlusion) and isolated without
retinal diseases.
2.3. Vitreomacular Traction. IVTSpostulated that vitreomac-
ular traction (VMT) is characterized by macular attachment
of the vitreous cortex within a 3-mm radius of the fovea
with distortion of the foveal surface, intraretinal pseudocyst
formation, and elevation of the fovea from the retinal pigment
epithelium (RPE). In VMT, the retinal layer should display no
full-thickness interruptions [20]. VMT may be subclassified
into focal (≤1500𝜇m) or broad (>1500 𝜇m) like VMAaccord-
ing to the width of macular attachment. Furthermore, VMT
can be termed concurrent or isolated, like VMA as previously
described. However, it can be challenging to differentiate bet-
ween VMT and VMA in eyes with neovascular AMD which
have irregular retinal surfaces owing to underlying CNV and
intraretinal cysts. In this review, we will focus on VMA but
not VMT and discuss the effects of VMA in AMD.
3. The Roles of Vitreomacular
Adhesion in Neovascular Age-Related
Macular Degeneration
3.1. Inflammation and Oxidative Stress. Many immune-
related genes that can induce inflammation, including age-
related maculopathy susceptibility 2 (ARMS 2), complement
factor H (CHF), and interleukin-8, are risk factors for AMD.
Therefore, we speculate that inflammation can contribute to
AMD pathogenesis [22, 23]. Inflammation can trigger tis-
sue injury, oxidative stress, extracellular matrix remodeling,
angiogenesis, and fibrosis in injured tissue [24]. In addition,
retinal circulation has high metabolic rates with respect to
oxygen consumption and the mitochondrial oxidative path-
way, including phototransduction, neurotransmitter utiliza-
tion, and protein/organelle transport [25, 26]. Dysregulation
between oxidative stress and repair processes can lead to
damage at the level of RPE cells, which cause AMD [27,
28]. VMA can induce chronic, low-grade inflammation with
mechanical forces that can aggravate AMD [6]. However,
there is currently no definite evidence whether VMA can
cause the development of neovascular AMD or whether
VMA is a consequence of the inflammation in neovascular
AMD.
3.2. Tractional Macular Detachment, Retinoschisis, and Mac-
ular Edema Formation. Intraretinal cysts and retinoschisis
can be induced by VMA according to Newton’s third law: for
every action, there is always an equal and opposite reaction
[29]. When anomalous PVD gives rise to tractional force at
the retina, there is an equal force in the opposite direction.
This causes the retinal tissue of the retina to be pulled apart
and leads to tractional macular detachment and retinoschisis
formation [30]. In addition, interstitial tissue pressure dec-
reases when the retina is pulled apart, which results in an
influx of the fluid from blood vessels according to Starling’s
law of hydrostatic pressure [21]. This fluid influx contributes
to the macular edema that is clearly evident in neovascular
AMD.
3.3. Decreased Vitreous Oxygenation. The retina has dual
blood supply from both choroidal and retinal circulation.
Choroidal circulation primarily supplies the outer retina,
which includes the highlymetabolic photoreceptors andRPE,
while retinal circulation supplies the inner retina [31]. How-
ever, some studies have proposed that the retina might be
partially oxygenated by the vitreous [32, 33]. The speed of
diffusion is inversely related to the viscosity of the vitreous.
Therefore, vitrectomized eyes that have a lower viscosity than
intact eyes show increased vitreous oxygenation in both
humans and animals [34–36]. Complete PVD induced by
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ocriplasmin also increases vitreous oxygen levels in the vit-
reous cavity [37]. Conversely, VMA, which is mostly located
over the area of the CNV in neovascular AMD [8, 38], may
disturb oxygenation from the vitreous to the retina.
3.4. Increased VEGF and Proangiogenic Cytokines in front of
the Macula. Increased VEGF can cause CNV in AMD and
the current gold standard treatment for AMD is anti-VEGF
treatment with ranibizumab or bevacizumab [10, 39]. In
neovascular AMD, the prevalence of retinal vascular abnor-
malities is increased [40]. VEGF and other proangiogenic
cytokines can diffuse into the vitreous cavity from these
abnormal retinal vessels [41]. Vitreous collagen fibrils are
altered with aging, and VEGF and other cytokines can be
retained by binding to altered collagen fibrils between ILM
and posterior vitreous cortex in VMA above the CNV area
[42].This can cause an increase in the concentration of VEGF
and other proangiogenic cytokines in front of themacula and
they can aggravate neovascularization and inflammation.
3.5. Expression of VEGF by Mechanical Stretch. Many studies
have shown that mechanical stretching of the retina can
induceVEGF expression [43–46]. A previous study supposed
that VMA can disrupt choroidal blood supply to the retina
and lead to hypoxia and result in increased VEGF levels [43].
Mechanical stress can also be an important regulator of gene
expression, protein synthesis, growth, and the differentiation
of many cell types [44]. Recent in vitro studies show that
mechanical stress on RPE cells can induce elevated levels of
succinate, which results in increased VEGF expression [45].
4. VMA and Neovascular AMD
It is generally accepted that there is an association between
VMA and neovascular AMD. A recent meta-analysis on the
prevalence of VMA in AMD reported that VMA in eyes with
neovascular AMD, dry AMD, and normal controls were
22.6%, 9.5%, and 7.7%, respectively.Thus, eyes with neovascu-
lar AMD are 2.15 timesmore likely to have VMA than normal
controls [47]. However, there is a controversy regarding prog-
nosis after anti-VEGF treatment in VMA with neovascular
AMD.
Some studies have reported that VMA is associated with
poor visual outcome after anti-VEGF treatment for neo-
vascular AMD. Lee and Koh reported that visual acuity
after intravitreal anti-VEGF treatment decreased from 0.87
logarithm of the Minimum Angle of Resolution (logMAR)
to 0.98 logMAR in eyes with VMA (3.87 injections per year)
and improved from 0.82 logMAR to 0.72 logMAR in eyes
without VMA (3.58 injections per year) between baseline
and the 12 months of follow-up [13]. U¨ney et al. showed that
eyes with VMA had a tendency to lose 4.9 early treatment
diabetic retinopathy study (ETDRS) letters in eyes with VMA
(3.5 injections per year) and gain 9.2 ETDRS letters in eyes
withoutVMA(4.0 injections per year) after 12months of anti-
VEGF treatment [14]. Nomura et at. also described that visual
acuity was unchanged from 0.42 logMAR to 0.39 logMAR in
eyes with VMA (5.1 injections per year) but increased from
0.41 logMAR at baseline to 0.29 logMAR in eyes without
VMA (5.2 injections per year) within the 12-month follow-
up period [15].
A randomized, double-masked, active-controlled, multi-
center study comparing the efficacy and safety of ranibizumab
administered as two dosing regimens in patients with sub-
foveal choroidal neovascularization secondary to age-related
macular degeneration (EXCITE) compared the efficacy of
monthly versus quarterly ranibizumab injections after a load-
ing phase for eyes with neovascular AMD and also investi-
gated the influence of VMA on the efficacy of ranibizumab
[48]. The EXCITE study group divided patients into three
groups: (1) PVD, patients with PVD; (2) RELEASE, patients
with VMA at first but not at last follow-up; and (3) VMA,
patients with persistent VMA. In a protocol of quarterly
injections after a loading phase (six injections per year),
mean changes in ETDRS letters were +4.7 for PVD, +3.2 for
RELEASE, and −0.2 for VMA within 12 months. These data
were similar to results reported by Lee and Koh, U¨ney et al.,
and Nomura et al. from the viewpoint that eyes with VMA
have poorer responses to anti-VEGF treatment [13–15].
However, in the monthly injection protocol group (12
injections per year) of the EXCITE study, the mean gains
in ETDRS letters were +4.9 for PVD, +12.7 for RELEASE,
and +7.5 for VMA. With continuous anti-VEGF injections,
RELEASE and VMA groups, which include patients with
VMA at baseline, showed better visual acuity than the PVD
group after 12 months of follow-up [48]. They speculated
that visual outcomes of neovascular AMD with VMA dif-
fered according to the frequency of intravitreal ranibizumab
injections, and eyes with VMA in neovascular AMD can
achieve favorable vision outcomes through an aggressive and
continuous injection protocol.
Waldstein et al. investigated the influence of VMA on the
efficacy of pro re nata (PRN) anti-VEGF injections after a
loading phase. They reported that changes in ETDRS letters
from baseline to the 12-month follow-up visit were +3.5 for
PVD, +4.3 for RELEASE, and +6.3 for VMA, which were not
significantly different [49]. In contrast to other studies that
showed no significant differences in the number of anti-
VEGF injections between eyes with VMA and without VMA,
there were more injections in the RELEASE (6.6 injections
per year) andVMAgroups (5.3 injections per year) compared
to the PVD group (4.9 injections per year).
Recently, the comparison of AMD treatments trials
(CATT) study for 2 years of follow-up compared the visual
acuity and number of injections according to the presence of
VMA or VMT assessed by OCT [50]. In 598 eyes treated as
needed protocol, there were 90 eyes (15.1%) with VMA at any
time, 63 eyes (10.5%)withVMTat any time, and 445 eyeswith
neither VMA nor VMT at any time. Visual acuity outcomes
between groups were not significantly different (𝑃 = 0.70).
However, there were more frequent injections in VMA group
and VMT group compared with the neither VMA nor VMT
group (13.8±0.73, 15.4±0.87, and 12.9±0.35, resp.,𝑃 = 0.02).
Overall, it is probable that eyes with VMA and neovascu-
lar AMDmay be less effective to loading plus PRN treatment,
which is one of the most common protocols for neovascular
AMD. A greater number of anti-VEGF injections in eyes with
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VMA and neovascular AMD might be helpful to achieve
similar visual outcomes in eyes without VMA, and even
favorable visual outcomes can be attained with continuous
anti-VEGF injections. A strategy for reducing the number
of anti-VEGF injections should also be considered in eyes
with VMA and neovascular AMD, as continuous injections
can cause an excessive financial burden and induce a greater
chance of developing geographic atrophy which can lead to
marked loss of visual acuity and function [51].
5. Treatment Options for Eyes with
VMA and Neovascular AMD
5.1. Vitrectomy. Ikeda et al. first performed vitrectomy for 12
eyes of 11 patients with VMA and neovascular AMD. After 6
months, CNV regressed in six eyes (50%) and completely dis-
appeared in two eyes (17%).Moreover, visual acuity improved
in four eyes, was maintained in four eyes, and decreased in
four eyes [52].Mojana et al. performed vitrectomy in five eyes
with VMT, and four of the five eyes showed an improvement
in visual acuity and a decrease in central foveal thickness on
OCT [7]. Furthermore, two case series reported that vitrec-
tomy can induce CNV regression in patients with VMT and
neovascular AMD [53, 54]. Sakamoto et al. showed that CNV
can regress or disappear after vitrectomy (40/54 eyes) and
CNV settledmore significantly in eyes with PVD than in eyes
without PVD [55]. Schramm et al. investigated the efficacy
and safety of a core vitrectomy in patients with neovascular
AMD treated with anti-VEGF therapy and they concluded
that core vitrectomy might produce similar functional out-
comes with respect to decreasing the number of intravitreal
ranibizumab injections required over 48 weeks, even though
it can induce more CNV bleeding [56].
All of these studies demonstrate that vitrectomy can
improve functional and anatomical outcomes or reduce the
number of anti-VEGF injections in eyes with VMA and neo-
vascular AMD. Benefits of vitrectomy can be achieved by
increasing oxygen diffusion from the anterior chamber to the
vitreous cavity and diffusion of VEGF and other proangio-
genic cytokines that are trapped between the posterior vit-
reous and ILM [7]. Furthermore, in vitrectomized eyes, the
passage of anti-VEGF from the vitreous to subretinal space
is not disturbed by the posterior vitreous cortex during anti-
VEGF treatment. However, prospective studies are necessary
to confirm the role of vitrectomy in AMD pathogenesis and
progression.
5.2. Pharmacologic Vitreolysis. Vitreolytic agents are classi-
fied into (1) interfactants that can weaken VMA (e.g., dis-
pase), (2) liquefactants that can induce vitreous liquefaction
(e.g., hyaluronidase), or (3) a combination of both (e.g., plas-
min, ocriplasmin, and tissue plasminogen activator) [57]. Of
these agents, plasmin acts on glycoproteins, including fibro-
nectin and laminin, without damaging the retina and has
been widely studied. However, plasmin’s use is limited in
patients owing to its rapid autolytic properties and the fact
that it requires activation by proenzymes and plasminogen,
which are not commercially available.
Ocriplasmin (JETREA, ThromboGenics Inc., Iselin, NJ,
USA) is an alternative to plasmin that was recently approved
for the treatment of symptomatic VMA in theUSA and Euro-
pean Union [58]. Ocriplasmin is a human serine protease
that contains the catalytic domain of plasmin. Ocriplasmin
is more stable than plasmin and can induce vitreous liquefac-
tion and cleave the vitreoretinal interface by degrading “glue”
proteins, including fibronectin and laminin [57–59].
The microplasmin for intravitreous injection-traction
release without surgical treatment (MIVI-TRUST) study
group showed thatVMAwas resolved in 26.5%of eyes treated
by a single injection of ocriplasmin (125 𝜇g in 0.10mL), com-
pared with 10.1% of eyes in the sham injection group within
28 days [59]. VMA resolution can be achieved more often in
younger patients (<65 years), patients with focal VMA (adhe-
sion diameter ≤ 1500𝜇m), phakic patients, and patients with-
out epiretinal membranes. Moreover, visual acuity improve-
ment was better in younger patients (<65 years) and patients
with lower baseline visual acuity (Snellen equivalent < 20/50)
[60].
Recently, a phase II clinical trial evaluating the safety and
efficacy of ocriplasmin in eyes with VMA and neovascular
AMD was performed [61]. Their data showed that VMA
was released in 24.3% (18/74) of the eyes in the ocriplasmin
injection group compared with 12.0% (3/25) of eyes in the
sham injection group at day 28 after injection. In addition, the
ocriplasmin injection group received fewer anti-VEGF injec-
tions compared with the sham injection group during the
12-month study period (4.4 injections versus 6.1 injections).
However, their study showed no significant differences in
VMA resolution or injection numbers between ocriplasmin
and sham injection groups owing to the limited sample size.
It is hypothesized that ocriplasmin can release VMA and
reduce the number of anti-VEGF injections required in neo-
vascular AMD, but additional studies with larger sample sizes
should be performed to confirm the efficacy of ocriplasmin in
patients with VMA and neovascular AMD.
5.3. Gas Injection. Gross-Jendroska et al. found that perfluo-
ropropane (C
3
F
8
) gas injection improved pigment epithelial
detachment caused by AMD [62]. Kim et al. reported that
all four patients achieved VMA release in neovascular AMD
when intravitreal perfluoropropane gas was injected [63].
Moreover, there were no adverse events, such as endoph-
thalmitis, cataract progression, increased intraocular pres-
sure, intraocular hemorrhage, or retinal detachment, during
follow-up. Rodrigues et al. reported that VMA was released
in 40% of eyes (6/14) within 1 month and 60% of eyes (9/14)
within 6 months by pure perfluoropropane injection [64].
Another case series also reported that pure perfluoropropane
injection induced PVD without serious adverse effects [65].
Therefore, pure perfluoropropane injection can be an option
for releasing VMA in neovascular AMD.
5.4. Intravitreal Injection. In the MIVI-TRUST study, sham
injections with 0.10mL saline were performed in the placebo
group, and spontaneous resolution ofVMAoccurred in 10.1%
of eyes 28 days after injection [59, 60]. This means that
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the sham injection itself can affect VMI via mechanical force,
without the enzymatic activity of ocriplasmin. There are
many studies that speculate that the intravitreal injection
itself can alter intraocular structures, including the vitreous,
retina, and anterior chamber, by mechanical force and other
unknown mechanisms [66, 67].
In eyes with neovascular AMD, multiple anti-VEGF
injections are necessary to maintain visual outcome. As a
result of multiple intravitreal injections, more eyes achieve
VMA resolution during the injection period. In the EXCITE
study, about half of the eyes with VMA experienced release
at 12 months (29/54 in the quarterly injection group, 19/31 in
the monthly injection group) [47]. Despite the fact that this
sample included some cases in which spontaneous resolution
occurred in eyes with VMA during the treatment period,
multiple injections can affect the release of VMA in eyes with
neovascular AMD.
5.5. Combined Therapy (Anti-VEGF Plus Photodynamic Ther-
apy). One study compared the effects of anti-VEGF mono-
therapy and anti-VEGF plus photodynamic therapy (PDT) in
eyes with VMA of neovascular AMD. The study concluded
that compared to anti-VEGF monotherapy, anti-VEGF plus
PDT helped reduce the number of injections in eyes with
VMA.The anti-VEGF plus PDT group also showed a trend of
superior visual outcome, but this was not clinically significant
[49]. Even if PDT did not relieve the VMA in neovascular
AMDdirectly, it can reduce the number of injections, thereby
ameliorating the financial burden and serious adverse events.
6. Conclusion
Clinical data shows that the probability of having VMA is
twice great in eyes with neovascular AMD than in normal
eyes [47]. VMA can affect neovascular AMD by (1) inducing
inflammation and oxidative stress, (2) formation of macular
detachment, retinoschisis, and macular edema, (3) decreas-
ing of vitreous oxygenation, (4) trapping VEGF and proan-
giogenic cytokines in front of the macula, and (5) mechanical
stress induced VEGF production. As eyes with VMA and
neovascular AMD have a tendency to generate a poorer res-
ponse to routine PRN anti-VEGF injection protocols, more
aggressive and continuous anti-VEGF injections might be
required to achieve favorable visual outcomes in this cohort.
VMA release can improve responsiveness to anti-VEGF
treatments, and the required number of anti-VEGF treat-
ments decreases as a result. Release of VMA can be achieved
by (1) vitrectomy, (2) ocriplasmin injection, (3) gas injection,
or (4) the repeated injection procedure itself. To decrease the
number of injections, combination therapy (PRN plus PDT)
should be considered.
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